SHANGHAI – When investors started pouring capital into Chinese biotechs like Hua Medicine Ltd., Innovent Biologics Inc. or Cstone Pharmaceuticals Co. Ltd., it was reasonable to wonder what exits they were planning. For a long time, China's major stock exchanges only allowed revenue-generating firms to list, making Nasdaq often the best bet, if not an ideal solution for Chinese biotechs.